+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Inhibitor design for SARS coronavirus main protease based on "distorted key theory"



Inhibitor design for SARS coronavirus main protease based on "distorted key theory"



Medicinal Chemistry ) 3(1): 1-6



In order to find effective peptide inhibitors against SARS CoV M(pro), an analysis was performed for 11 oligo-peptides that can be cleaved by the SARS coronavirus main protease (CoV M(pro), or 3CL(pro)). Flexible molecular alignments of the 11 cleavable peptides have provided useful insights into the chemical properties of their amino acid residues close to the cleavage site. Moreover, it was found through the ligand-receptor docking studies that of the 11 cleavable peptides, NH2-ATLQ / AIAS-COOH and NH2-ATLQ / AENV-COOH had the highest affinity with SARS CoV M(pro). The two octapeptides were selected as initial templates for further chemical modification to make them become effective inhibitors against the SARS enzyme according to the "distorted key" theory [K. C. Chou, Analytical Biochemistry 233 (1996) 1-14]. The possible chemical modification methods are proposed and examined. The approach developed in this study and the findings thus obtained might stimulate new strategies and provide useful information for drug design against SARS.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 049360064

Download citation: RISBibTeXText

PMID: 17266617


Related references

Inhibitor Design for Sars Coronavirus Main Protease Based on Distorted Key Theory. Medicinal Chemistry 3(1): 1-6, 2007

Evaluation of homology modeling of the severe acute respiratory syndrome (SARS) coronavirus main protease for structure based drug design. Chemical & Pharmaceutical Bulletin 52(5): 643-645, 2004

Synergistic inhibitor binding to the papain-like protease of human SARS coronavirus: mechanistic and inhibitor design implications. Chemmedchem 8(8): 1361-1372, 2013

Substrate specificity and rational design of peptidomimetic inhibitors for SARS coronavirus main protease. Hong Kong Medical Journal 20(Suppl. 4): 18-21, 2014

An efficient method for the synthesis of peptide aldehyde libraries employed in the discovery of reversible SARS coronavirus main protease (SARS-CoV Mpro) inhibitors. Chembiochem 7(7): 1048-1055, 2006

Exploring the binding mechanism of the main proteinase in SARS-associated coronavirus and its implication to anti-SARS drug design. Bioorganic and Medicinal Chemistry 12(9): 2219-2223, 2004

Characterization and Inhibition of Sars-Coronavirus Main Protease. Current Topics in Medicinal Chemistry 6(4): 361-376, 2006

Characterization and inhibition of SARS-coronavirus main protease. Current Topics in Medicinal Chemistry 6(4): 361-376, 2006

Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry 43(17): 4906-4912, 2004

Mechanism for controlling the monomer-dimer conversion of SARS coronavirus main protease. Acta Crystallographica. Section D Biological Crystallography 69(Pt 5): 747-755, 2013

Mutation of Glu-166 blocks the substrate-induced dimerization of SARS coronavirus main protease. Biophysical Journal 98(7): 1327-1336, 2010

Quaternary structure of the severe acute respiratory syndrome (SARS) coronavirus main protease. Biochemistry 43(47): 14958-14970, 2004

Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease. Antiviral Research 92(2): 204-212, 2011

Hiv protease inhibitor nelfinavir inhibits replication of Sars-associated coronavirus. Biochemical and Biophysical Research Communications 318(3): 719-725, 2004

HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochemical and Biophysical Research Communications 318(3): 719-725, 2004